title: Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper.
abstract: Forty-eight patients with panic disorder completing 8 months of maintenance treatment with alprazolam (mean dose, 5.2 mg [n = 27]), imipramine hydrochloride (mean dose, 175 mg [n = 11]), or placebo (mean dose, 8.0 pills [n = 10]) underwent a gradual taper from medication over a 4-week period. A withdrawal syndrome was observed in almost all alprazolam-treated patients but in only a few imipramine- or placebo-treated patients. The clinical worsening of withdrawal symptoms after discontinuation tended to subside over the course of 3 medication-free weeks, but 33% of alprazolam-treated patients were unable to discontinue their medication regimen successfully. Severity of panic attacks at baseline but not daily alprazolam dose appeared as a significant independent predictor of taper difficulty. Forty-nine percent of the total study population continue to receive drug therapy: 82% alprazolam and 18% imipramine. Among patients who received alprazolam during study treatment and at follow-up, the mean daily dose was substantially reduced (6.1 vs 1.6 mg [n = 14]). At follow-up, after 1 year of naturalistic treatment for panic symptoms and combining 8-month completers and study dropouts, there were no significant differences in remission (68% to 71%) or in antipanic medication intake (39% to 56%) at follow-up for the three original treatment groups. However, 8-month study completers compared with study dropouts had a significantly higher remission rate (85% vs 55%).
authors.affiliation: Department of Psychiatry, University of Pennsylvania, PA.
authors.forename: K
authors.initials: K
authors.lastname: Rickels
authors.forename: E
authors.initials: E
authors.lastname: Schweizer
authors.forename: S
authors.initials: S
authors.lastname: Weiss
authors.forename: S
authors.initials: S
authors.lastname: Zavodnick
mesh_terms: D000328:Adult; D000525:Alprazolam / Q000009:adverse effects / Q000627:therapeutic use*; D000553:Ambulatory Care; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D016584:Panic Disorder / Q000175:diagnosis / Q000517:prevention & control* / Q000523:psychology; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012008:Recurrence; D012720:Severity of Illness Index; D013375:Substance Withdrawal Syndrome / Q000453:epidemiology / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D010919:Placebos; D007099:Imipramine; D000525:Alprazolam